You can buy Afanat at the lowest price in the online pharmacy Nextgen.ooo . Afatinib is an anticancer drug used to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations or resistance to platinum-based chemotherapy. Afatinib is a potent and selective irreversible ErbB family blocker. Afatinib covalently binds to and irreversibly blocks signaling from all homo- and heterodimers formed by ErbB family members EGFR (ErbB1), HER2 (ErbB2), ErbB3, and ErbB4. Specifically, afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2. (ErbB2) and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of the ErbB signaling mark.
 
Certain mutations in EGFR, including non-resistant mutations in its kinase domain, can result in increased receptor autophosphorylation, leading to receptor activation, sometimes in the absence of ligand binding, and may support cell proliferation in NSCLC. Non-resistant mutations are defined as mutations occurring in exons comprising the kinase domain of EGFR that result in increased receptor activation and whose efficacy is determined by 1) clinically meaningful tumor shrinkage at the recommended dose of afatinib and/or 2) inhibition of cell proliferation or EGFR tyrosine kinase phosphorylation at afatinib concentrations sustained at the recommended dose according to validated label methods. The most common of these mutations are exon 21 L858R substitutions and exon 19 deletions.
 
Furthermore, afatinib demonstrated inhibition of autophosphorylation and/or proliferation in vitro in cell lines expressing wild-type EGFR, as well as in lines expressing individual EGFR exon 19 deletion mutations, exon 21 L858R mutations, or other less common non-resistant mutations. In addition, afatinib inhibited in vitro proliferation of cell lines overexpressing HER2.